| Home |
|
|
|
Neurodegenerative
Diseases Tx/Dx CI - Y2006 week 43 |
|
|
| DATE |
SOURCE |
OTHER PARTY INVOLVED |
INDICATION(S) |
HEADLINES - CLICK TO VIEW FULL
RELEASE |
|
|
| 10/27/06 |
Schwarz Pharma (DE) |
|
Parkinson |
Nine Months Report 2006: Business on
Track, Further Progress in R&D |
| 10/27/06 |
Shire (UK) |
Janssen
Pharmaceutical (US) |
Alzheimer |
Excellent third quarter with execution
plan on track - upgrading 2006 revenue guidance |
| 10/26/06 |
Case Western Reserve University (US) |
Ohio Center for
Neural Repair (US) |
Various |
Case Western Reserve University School
of Medicine, Cleveland Clinic and Area Companies Team to Create Ohio Center
for Neural Repair |
| 10/26/06 |
Diamyd Medical (SE) |
Neurologix (US) |
Parkinson |
Year End Report for Diamyd Medical AB
(publ) |
| 10/26/06 |
Millennium Pharmaceuticals (US) |
|
Multiple
sclerosis |
Millennium Achieves Non-GAAP
Profitability and Reduces GAAP Net Loss for Third Consecutive Quarter(1) |
| 10/26/06 |
MultiCell Technologies (US) |
|
Multiple
sclerosis |
MultiCell Technologies Recaps New
Investor Conference Call Discussing Recent Drug Development Initiatives and
Strengthened IP Portfolio |
| 10/26/06 |
NeoStem (US) |
|
Multiple
sclerosis |
NeoStem, Inc. Appoints Julio C. Guerra,
MD, ABP, as Director of Sales and Marketing |
| 10/26/06 |
Sepracor (US) |
|
Parkinson |
Sepracor Announces Third Quarter 2006
Operating Results |
| 10/26/06 |
The Immune Response (US) |
Spelman Research (US) |
Multiple
sclerosis |
Spelman Research Initiates Coverage of
The Immune Response Corporation With Price Target of $0.059 Per Share |
| 10/26/06 |
University of Liverpool (UK) |
IntelliHep (UK) |
Alzheimer |
Scientists develop new treatments for
Alzheimer's disease |
| 10/26/06 |
Viropro (CA) |
NRC-BRI (CA) |
Multiple
sclerosis |
Acquisition of a Worldwide Exclusive
License-Production of Recombinant Human Interferon Beta |
| 10/25/06 |
Accelerated Cure
Project for Multiple Sclerosis (US) |
|
Multiple
sclerosis |
Accelerated Cure Project Launches MS
Repository, World's Largest Biobank for Multiple Sclerosis Research |
| 10/25/06 |
Affymetrix (US) |
Translational Genomics Research
Institute (US) |
Various |
Affymetrix Reports Third Quarter 2006
Results |
| 10/25/06 |
Allon Therapeutics
(CA) |
|
Various |
Allon Therapeutics launches $8-million
financing October 25th, 2006 |
| 10/25/06 |
Case Western Reserve University (US) |
Rett Syndrome Research Foundation (US) |
Rett syndrome |
Case School of Medicine professor
discovers nerve cell defects caused by mental retardation gene |
| 10/25/06 |
CoLucid Pharmaceuticals (US) |
|
Alzheimer |
CoLucid Names James F. White as
President and Chief Executive Officer |
| 10/25/06 |
Elan (IR) |
|
Various |
Elan Reports Third Quarter 2006
Financial Results |
| 10/25/06 |
N.I.E.H.S. (US) |
Perlegen Sciences (US) |
Parkinson |
Mouse DNA to Aid Biomedical Research |
| 10/25/06 |
Pharmos (IL) |
Vela Pharmaceuticals (US) |
Multiple
sclerosis |
Pharmos Shareholders Approve Vela
Pharmaceuticals Transaction |
| 10/25/06 |
Targeted Genetics
(US) |
|
Huntington |
Targeted Genetics Receives Patent for
Enhanced Core Technology Including Expressed RNA |
| 10/24/06 |
BioMS Medical (CA) |
|
Multiple
sclerosis |
BioMS Medical expands pivotal multiple
sclerosis trial into the Baltic States |
| 10/24/06 |
Cortex Pharmaceuticals (US) |
|
Various |
Cortex to Hold Conference Call on
October 26 Following Release of CX717 from FDA Clinical Hold |
| 10/24/06 |
MultiCell Technologies (US) |
|
Multiple
sclerosis |
MultiCell Establishes Clinical
Development Team to Lead UK Phase IIb Human Clinical Trials for MCT-125 for
the Treatment of Fatigue in MS Patients |
| 10/24/06 |
ProNAi Therapeutics (US) |
|
Alzheimer |
ProNAi Closes Successful Bridge Funding
Round, Secures $6.65 Million Total |
| 10/24/06 |
Targacept (US) |
|
Alzheimer |
Targacept Announces Addition of Alan W.
Dunton, M.D. to Its Board of Directors |
| 10/24/06 |
Tiantan Puhua
Neurosurgical Hospital (CN) |
|
Parkinson |
Stem Cell Treatment Proven to Reduce
Parkinson's Symptoms |
| 10/23/06 |
Acumen Pharmaceuticals (US) |
Neurotechnology
Industry Organization (US) |
Alzheimer |
Acumen Joins Neurotechnology Industry
Organization |
| 10/23/06 |
Amgen (US) |
|
Alzheimer |
Amgen's Third Quarter 2006 Adjusted
Earnings Per Share, Excluding Stock Option Expense, Increased 22 Percent to
$1.04 GAAP Earnings Per Share… |
| 10/23/06 |
Athenagen (US) |
|
Alzheimer |
Athenagen Expands Leadership Team With
Two Seasoned Drug Development Professionals |
| 10/23/06 |
Berlex (US) |
Schering (DE) |
Multiple
sclerosis |
FDA Approves Betaseron(R) for Use After
the First Event Suggestive of Multiple Sclerosis |
| 10/23/06 |
Medivir (SE) |
|
Multiple
sclerosis |
Medivir, Interim Report, 1 January - 30
September 2006 |
| 10/23/06 |
MultiCell Technologies (US) |
|
Multiple
sclerosis |
MultiCell Technologies to Host Investor
Conference Call to Discuss Progress in Development Programs and Growth of IP
Portfolio CEO to Spotlight Lead New.. |
| 10/23/06 |
NeuroSearch (DK) |
A. Carlsson Research
(SE) |
Huntington |
NeuroSearch closes acquisition of A.
Carlsson Research AB and adjusts its outlook for the full year and warrant
programmes |
| 10/23/06 |
Santhera Pharmaceuticals (CH) |
|
Parkinson |
Santhera announces an Initial Public
Offering and subsequent listing on the SWX Swiss Exchange |
| 10/23/06 |
Schering (DE) |
Berlex (US) |
Multiple
sclerosis |
Betaseron approved in the U.S. for
earliest stages of Multiple Sclerosis |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|